The collaboration will seek to foster the adoption of appropriate protocols and pathways for the integration of ENBUMYST™ (bumetanide nasal spray) into clinical care with the goal of reducing readmissions, improving fluid management and enhancing outcomes through the novel delivery of diuretic therapy.
Corstasis Therapeutics Inc., an innovative biopharmaceutical company providing enhanced outpatient therapeutic options for patients with cardiovascular and renal disease, today announced a strategic collaboration with U.S. Heart and Vascular® (USHV), the nation’s premier cardiovascular management services organization, seeking to enable earlier intervention and enhance outcomes for heart failure patients. Corstasis and USHV will co-develop, and seek to optimize, value-based care pathways for the outpatient treatment of fluid overload in patients with congestive heart failure, liver disease and chronic kidney disease with ENBUMYST™ (bumetanide nasal spray).
“ENBUMYST was developed with the goal of giving providers a new, self-administered outpatient option,” said Brian Kolski M.D., Chief Medical Officer of Corstasis Therapeutics. “Our collaboration with USHV reflects a shared commitment to health system innovation, value-based care delivery and patient-centered outcomes.”
The collaboration between Corstasis and USHV will seek to:
- Develop and validate protocols and clinical workflows that are consistent with approved labeling and enable adoption of early intervention via nasal spray diuresis when clinically indicated
- Develop associated provider and staff training to ensure seamless integration of this important new intervention into clinical care
- Capture outcomes and healthcare economic data to support payer engagement and future reimbursement strategies
“At USHV, we are continuously seeking new tools that empower our affiliated physicians and deliver measurable value to patients and payers,” said Emily Rash, Chief Value-Based Care Officer, USHV. “We believe an outpatient-friendly alternative represents a meaningful step forward in ambulatory heart failure care and we’re proud to work with Corstasis to bring this innovation into practice.”
The U.S. Food and Drug Administration (FDA) recently approved ENBUMYST for the treatment of edema associated with congestive heart failure (CHF), and hepatic and renal disease, including nephrotic syndrome in adults.
This effort is intended to put Corstasis and USHV at the forefront of improving outpatient heart failure management, with the goal of enabling the option of earlier intervention, reduced escalation of care and a more cost-effective path to euvolemia. Fluid overload associated with CHF, liver disease and chronic kidney disease is responsible for driving millions of hospitalizations and readmissions annually.
